GlycoNex (ROCO:4168) OCF Margin %: -1,307.88% (As of Dec. 2025)


ROCO:4168 GlycoNex Inc ROCO:4168
56 GF Score
Price NT$25.60
GF Value NT$74.21
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is GlycoNex OCF Margin %?

GlycoNex ROCO:4168 +0.39% 56 OCF Margin % is -1,307.88% as of Dec. 2025. GuruFocus rates ROCO:4168 with a GF Score™ of 56/100 and a GF Value™ of NT$74.21 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 957 Biotechnology companies, GlycoNex ranks worse than 71.58% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. GlycoNex's Cash Flow from Operations for the three months ended in Dec. 2025 was NT$-57.61 Mil. GlycoNex's Revenue for the three months ended in Dec. 2025 was NT$4.41 Mil. Therefore, GlycoNex's OCF Margin % for the quarter that ended in Dec. 2025 was -1,307.88%.

As of today, GlycoNex's current OCF Yield % is -6.01%.

The historical rank and industry rank for GlycoNex's OCF Margin % or its related term are showing as below:

ROCO:4168' s OCF Margin % Range Over the Past 10 Years
Min: -45242.26   Med: -4904.07   Max: 9688.96
Current: -439.2


During the past 13 years, the highest OCF Margin % of GlycoNex was 9688.96%. The lowest was -45242.26%. And the median was -4904.07%.

ROCO:4168's OCF Margin % is ranked worse than
71.58% of 957 companies
in the Biotechnology industry
Industry Median: -66.52 vs ROCO:4168: -439.20


GlycoNex OCF Margin % Related Terms


GlycoNex OCF Margin % Historical Data

* Premium members only.

The historical data trend for GlycoNex's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlycoNex OCF Margin % Chart

GlycoNex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,572.80 -556.92 -7,235.33 -1,509.88 -439.20

GlycoNex Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,918.38 -326.83 -293.32 -448.96 -1,307.88

ROCO:4168 vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, GlycoNex's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoNex OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoNex's OCF Margin % distribution charts can be found below:

* The bar in red indicates where GlycoNex's OCF Margin % falls into.


ROCO:4168
56GF Score
GlycoNex Inc ROCO:4168
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlycoNex OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

GlycoNex's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-166.287/37.861
=-439.20 %

GlycoNex's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-57.612/4.405
=-1,307.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -1,307.88% mean?
GlycoNex (ROCO:4168) has a OCF Margin % of -1,307.88% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on GlycoNex and its competitors. According to the industry distribution chart, GlycoNex ranks #685 out of 957 companies in the Biotechnology industry, placing it in the top 71.6%.
Is GlycoNex's OCF Margin % too high?
GlycoNex's current OCF Margin % is -1,307.88%. Based on the distribution chart, GlycoNex ranks #685 out of 957 companies in the Biotechnology industry, which is below the industry midpoint. Overall, GlycoNex has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlycoNex's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GlycoNex ranks #685 out of 957 companies for OCF Margin %. This places GlycoNex in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on GlycoNex and its competitors. GlycoNex's current OCF Margin % is -1,307.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlycoNex stock overvalued right now?
Based on GuruFocus' analysis, GlycoNex (ROCO:4168) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$74.21, compared to a current price of NT$25.60 — trading 65.5% below its estimated fair value. The current OCF Margin % is -1,307.88%. GlycoNex's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For GlycoNex (ROCO:4168), the current OCF Margin % is -1,307.88% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlycoNex (ROCO:4168) Overvalued in 2026?

Based on GuruFocus' analysis, GlycoNex stock appears to be undervalued. The current stock price of NT$25.60 is trading 65.5% below its estimated GF Value™ of NT$74.21. GuruFocus considers GlycoNex to be Significantly Undervalued.

Key valuation signals for ROCO:4168:

  • OCF Margin %: -1,307.88%
  • GF Value™: NT$74.21 vs. price of NT$25.60 (65.5% below fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GlycoNex Business Description

Address Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221
GlycoNex Inc is a Taiwan-based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The other services provided by the firm include functional evaluation, antibody research, and antibody engineering. It has two reportable segments: antibody new drug, which derives maximum revenue, and exclusive investment. Geographically, the group derives maximum revenue from Taiwan and the rest from Japan.
56GF Score

Get the complete analysis for ROCO:4168

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$25.60
Price
NT$74.21
GF Value